perspective. METHODS: The IQVIA Core Diabetes Model (CDM) was calibrated to reproduce the outcomes from the EMPA-REG OUTCOME trial. Baseline characteristics and observed effects on physiological parameters (HbA1c, BMI, blood pressure, lipids) were used as inputs. Network meta-analysis provided the relative risks for cardiovascular outcomes with empagliflozin versus sitagliptin and saxagliptin. HbA1c progression for all arms was projected based on the EMPA-REG OUTCOME trial. The effects of the CVOTs were applied up until treatment switch (reaching HbA1c of 8.5%) after which, the UKPDS82 risk equations predicted events based on physiological parameters. Basal-bolus rescue therapy was assumed after reaching an HbA1c of 8.5%. UK event costs and quality of life data were taken from literature. Drug costs were from the British National Formulary and Monthly Index of Medical Specialities. Discounting of 3.5% was applied. RESULTS: CDM projected 5.923, 5.462, and 5.324 qualityadjusted life-years (QALYs) and 51,629GBP, 48,306GBP and 48,885GBP total lifetime costs for empagliflozin, sitagliptin and saxagliptin, respectively. The incremental cost-effectiveness ratio of empagliflozin versus sitagliptin and saxagliptin was 7,209GBP/QALY and 4,582GBP/QALY, respectively. One-way and probabilistic sensitivity analyses showed robustness of the results. CONCLUSIONS: The results of this cost effectiveness analysis suggested that empagliflozin + SoC was costeffective compared to sitagliptin + SoC and saxagliptin + SoC at a willingness to pay threshold of 20,000GBP/QALY.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.